Searched for
DIVIS EXPANSION
Divi’s Lab shares up 3% after Q4 PAT surges 26% YoY. Should you invest?Divi's Laboratories reported a strong Q4FY25, with a 26% YoY increase in net profit to Rs 667 crore and a 12.26% rise in revenue to Rs 2,53...- Vedanta, Divi’s, Bajaj Holdings, BEL, IndiGo among top wealth creator in FY25Vedanta led NSE 100's FY25 performance with an 87% TSR, driven by share price appreciation and dividends. Divi’s Laboratories, Bajaj Holdin...
- Divi’s Laboratories Q2 Results: Company posts 47% jump in net profit in Q2FY25Divi's Laboratories witnessed a 46.6% surge in profit, reaching Rs. 510 crores in Q2FY25, fueled by robust growth in their custom synthesis...
- Hot Stocks: Brokerage view on LIC, Biocon, Divi’s Laboratories and Bandhan BankKotak Institutional Equities recommended a sell on Divi’s Laboratories with a target price of Rs 3025. The company recorded a weakness in t...
- Motilal Oswal Financial Services neutral on Divi's Laboratories, target price-Rs 2620Promoters held 51.94 per cent stake in the company as of 31-Dec-2022, while FIIs owned 15.15 per cent, DIIs 20.5 per cent.
- Will Divi's business expansion boost its valuations?Indian pharma companies have been struggling to maintain margins because of strong headwinds. Due to increased competition, pharma companie...
- Up 670% in 4 years, this API maker’s adrenaline rush is simply not endingThe stock escaped the broader selloff of March 2020 and remained unfazed in the face of the Covid 2.0 volatility, as it kept on hitting rec...
- India’s best-performing stock is seeing a wave of optimistic callsThe optimism is stemming from the company’s capacity-expansion plans and potential to win more business as India cuts its reliance on Chine...
- Divi’s Labs hits all-time high after robust Q2 resultsA recent entrant to the Nifty pack, Divi’s Labs is up 82 per cent year-to-date, and has almost doubled over the last one year.
- Buy Divi's Laboratories, target price Rs 3350: Motilal OswalDivi's Laboratories Ltd., incorporated in the year 1990, is a Large Cap company (having a market cap of Rs 83957.09 Crore) operating in Pha...
- What makes the latest pharma company to enter Nifty very different from its peers in the index?Unlike its peers, Divi is a pure-play active pharma ingredients (API) company and does not face the same challenges and risks as that of it...
- Was June quarter show a one-time surprise from Divi’s Lab?During a spectacular rally on Monday post June quarter earnings, the stock beat the likes of Cipla and Aurobindo Pharma to become the secon...
- Buy Divi's Laboratories, target price Rs 3350: Motilal OswalDivi's Laboratories Ltd., incorporated in the year 1990, is a Large Cap company (having a market cap of Rs 85017.64 Crore) operating in Pha...
- Buy Divi's Laboratories, target Rs 1,600: Axis CapitalBuy Divi's Laboratories Ltd. at a price target of Rs 1600.
- Buy Divi's Laboratories, target Rs 1,670: SharekhanBuy Divi's Laboratories Ltd. at a price target of Rs 1670.
- Neutral on Divi's Laboratories, target Rs 1200: Motilal OswalNeutral Divi's Laboratories Ltd. at a price target of Rs 1200.0 .
- Buy Divi's Laboratories, target Rs 1,275: SharekhanBuy Divi's Laboratories Ltd. at a price target of Rs 1275.0 .
- Divis to spend Rs 300 crore on expansion plans in 2018The company spent about Rs 400 crore till December last year and will be spending another Rs 300 crore on the expansion programme during th...
- Divi’s Laboratories tanks over 6% on weak Q4 earnings, downgradeThe company posted 16.75 per cent decline in its consolidated net profit at Rs 180.57 crore for the fourth quarter ended March 31.
- Religare puts 'buy' on Divi's Lab; target Rs 1,833Religare Research has maintained ‘buy’ on Divi’s Laboratories for a target price of Rs 1,833. The company has reported in-line results for ...
Load More
